drugset / Trial / NCT05525780

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

NCT05525780

Phase 1 Completed 48 enrolled G2GBio, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM depot in healthy male volunteers. And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by PK modeling.

Timeline

Start
2022-08-26
Primary completion
2023-06-02
Completion
2023-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 10 mg Intramuscular
Subject Donepezil Small molecule 70 mg Intramuscular
Subject Donepezil Small molecule 140 mg Intramuscular
Subject Donepezil Small molecule 280 mg Intramuscular

Indications